The Antibody Innovation Alliance unites biotech leaders to shape FDA pathways and secure federal funding for next-generation antibody therapeutics. Together, we're building the policy environment innovation demands.
The Antibody Innovation Alliance represents the voice of biotech innovators before Congress and federal regulators. We navigate the complex intersection of cutting-edge science and policy, advocating for streamlined FDA approval pathways and robust federal research funding. Our members are committed to bringing life-changing antibody therapeutics to patients faster.
We believe innovation thrives when policy keeps pace with science. By mobilizing our coalition of industry leaders, we've successfully influenced FDA guidance documents, shaped congressional healthcare agendas, and strengthened federal investment in antibody research. Our collaborative approach bridges the gap between laboratory breakthroughs and regulatory reality.
We engage directly with Congress to advance bills and amendments that support antibody therapeutic development. Our team tracks legislative opportunities, mobilizes member testimony, and builds bipartisan coalitions to secure favorable policy outcomes.
We work with the FDA to streamline approval pathways for next-generation antibody programs. Our evidence-based advocacy informs guidance documents and accelerates patient access to innovative treatments.
We unite biotech companies, academic researchers, and patient advocates around shared policy goals. Our network amplifies member voices and creates lasting partnerships that drive systemic change.
Our leadership team includes former FDA officials, biotech executives, and seasoned policy strategists who understand both the science and the regulatory landscape.
Members have secured over $2.3 billion in federal research funding and accelerated regulatory timelines through our coordinated advocacy efforts.
Direct relationships with key congressional committees, FDA leadership, and fellow innovators ensure your voice reaches the decision-makers who matter.
Join 150+ biotech companies accelerating cures through smarter policy.
Contact Our Team